Sun J, Song S, Liu J, Chen F, Li X, Wu G
NPJ Biofilms Microbiomes. 2025; 11(1):43.
PMID: 40069181
PMC: 11897378.
DOI: 10.1038/s41522-025-00678-x.
Zou J, Xu B, Gao H, Luo P, Chen T, Duan H
Front Immunol. 2024; 15:1507355.
PMID: 39703512
PMC: 11655508.
DOI: 10.3389/fimmu.2024.1507355.
Simunic M, McGraw K, Pavletic S, Rashidi A
Semin Hematol. 2024; 61(6):442-448.
PMID: 39551677
PMC: 11646173.
DOI: 10.1053/j.seminhematol.2024.10.006.
Du Y, Zhang Y, Zhao W, Zhang Y, Su F, Zhang X
Hum Vaccin Immunother. 2024; 20(1):2398309.
PMID: 39267589
PMC: 11404634.
DOI: 10.1080/21645515.2024.2398309.
Reyes A, Muddasani R, Massarelli E
Cancers (Basel). 2024; 16(16).
PMID: 39199689
PMC: 11353073.
DOI: 10.3390/cancers16162919.
Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework.
Stringer A, Hargreaves B, Amaral Mendes R, Blijlevens N, Bruno J, Joyce P
Support Care Cancer. 2024; 32(8):558.
PMID: 39080025
PMC: 11289053.
DOI: 10.1007/s00520-024-08752-4.
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation.
Bukavina L, Ginwala R, Eltoukhi M, Sindhani M, Prunty M, Geynisman D
Cancer Res Commun. 2024; 4(6):1505-1516.
PMID: 38747616
PMC: 11181990.
DOI: 10.1158/2767-9764.CRC-23-0479.
Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects.
Liu Z, Zhang D, Chen S
J Exp Clin Cancer Res. 2024; 43(1):118.
PMID: 38641815
PMC: 11027554.
DOI: 10.1186/s13046-024-03034-7.
Influence of intestinal microbial metabolites on the abscopal effect after radiation therapy combined with immune checkpoint inhibitors.
Felchle H, Gissibl J, Lansink Rotgerink L, Nefzger S, Walther C, Timnik V
Clin Transl Radiat Oncol. 2024; 46:100758.
PMID: 38500667
PMC: 10945164.
DOI: 10.1016/j.ctro.2024.100758.
Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender....
Teijeira L, Martinez M, Moreno A, de Elejoste I, Ibanez-Beroiz B, Arrazubi V
Cancers (Basel). 2024; 16(1).
PMID: 38201577
PMC: 10778233.
DOI: 10.3390/cancers16010151.
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours.
Fuller-Shavel N, Krell J
Curr Oncol Rep. 2024; 26(2):164-174.
PMID: 38194216
PMC: 10890979.
DOI: 10.1007/s11912-023-01492-4.
Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers.
Miao Y, Quan W, Tang X, Shi W, Li Q, Li R
Int J Biol Sci. 2024; 20(2):621-642.
PMID: 38169638
PMC: 10758091.
DOI: 10.7150/ijbs.89376.
Mechanisms by which the intestinal microbiota affects gastrointestinal tumours and therapeutic effects.
He J, Li H, Jia J, Liu Y, Zhang N, Wang R
Mol Biomed. 2023; 4(1):45.
PMID: 38032415
PMC: 10689341.
DOI: 10.1186/s43556-023-00157-9.
Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.
Del Gaudio A, Di Vincenzo F, Petito V, Giustiniani M, Gasbarrini A, Scaldaferri F
Inflamm Bowel Dis. 2023; 30(6):1018-1031.
PMID: 37801695
PMC: 11144981.
DOI: 10.1093/ibd/izad229.
Progresses in biomarkers for cancer immunotherapy.
Lin X, Zong C, Zhang Z, Fang W, Xu P
MedComm (2020). 2023; 4(5):e387.
PMID: 37799808
PMC: 10547938.
DOI: 10.1002/mco2.387.
Tracing the evolving dynamics and research hotspots of microbiota and immune microenvironment from the past to the new era.
Huang R, Yao Y, Tong X, Wang L, Qian W, Lu J
Microbiol Spectr. 2023; :e0013523.
PMID: 37768071
PMC: 10581186.
DOI: 10.1128/spectrum.00135-23.
An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management.
Cheng Y, Ling F, Li J, Chen Y, Xu M, Li S
Front Immunol. 2023; 14:1190850.
PMID: 37404814
PMC: 10315615.
DOI: 10.3389/fimmu.2023.1190850.
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms.
Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J
Cell Biosci. 2023; 13(1):120.
PMID: 37386520
PMC: 10311815.
DOI: 10.1186/s13578-023-01073-9.
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.
Pabst L, Lopes S, Bertrand B, Creusot Q, Kotovskaya M, Pencreach E
Int J Mol Sci. 2023; 24(8).
PMID: 37108738
PMC: 10145126.
DOI: 10.3390/ijms24087577.
Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.
Hu X, Wang L, Shang B, Wang J, Sun J, Liang B
Front Immunol. 2023; 14:1094414.
PMID: 36949956
PMC: 10025397.
DOI: 10.3389/fimmu.2023.1094414.
